Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04491604 · ClinicalTrials.gov registry record · Phase 3
Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB
A Phase 3 study, sponsored by Krystal Biotech.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT04491604 is a Phase 3 study that has completed, run by Krystal Biotech. The registered enrollment target is 31 participants.
The verdict
NCT04491604, a Phase 3 study, has completed, sponsored by Krystal Biotech.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
To determine whether administration of topical B-VEC improves wound healing as compared to placebo, and to evaluate durability, repeat dosing (Primary Endpoint) and further obtain safety and tolerability data.
Interventions
- OTHER Placebo
- BIOLOGICAL Topical Beremagene Geperpavec
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2020-08-17 |
| Est. Completion | 2022-01-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04491604
The ClinicalTrials.gov registry entry for NCT04491604 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Krystal Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04491604 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04491604 about?
NCT04491604 is a clinical study titled "Ph 3 Efficacy and Safety of B-VEC for the Treatment of DEB". To determine whether administration of topical B-VEC improves wound healing as compared to placebo, and to evaluate durability, repeat dosing (Primary Endpoint) and further obtain safety and tolerability data.
What is the current status of trial NCT04491604?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2020-08-17. Estimated completion is 2022-01-14.
What interventions are being tested in trial NCT04491604?
The interventions under investigation include: Placebo (OTHER), Topical Beremagene Geperpavec (BIOLOGICAL).
Who is sponsoring clinical trial NCT04491604?
This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.